CA2581746A1 - Staphylococcus aureus isd protein-based anti-infectives - Google Patents

Staphylococcus aureus isd protein-based anti-infectives Download PDF

Info

Publication number
CA2581746A1
CA2581746A1 CA002581746A CA2581746A CA2581746A1 CA 2581746 A1 CA2581746 A1 CA 2581746A1 CA 002581746 A CA002581746 A CA 002581746A CA 2581746 A CA2581746 A CA 2581746A CA 2581746 A1 CA2581746 A1 CA 2581746A1
Authority
CA
Canada
Prior art keywords
isd
polypeptide
isda
isdb
isdc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002581746A
Other languages
English (en)
French (fr)
Inventor
David E. Heinrichs
Christie Vermeiren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Ontario
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2581746A1 publication Critical patent/CA2581746A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002581746A 2004-10-25 2005-10-25 Staphylococcus aureus isd protein-based anti-infectives Abandoned CA2581746A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62192104P 2004-10-25 2004-10-25
US60/621,921 2004-10-25
PCT/IB2005/004126 WO2006059247A2 (en) 2004-10-25 2005-10-25 VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC

Publications (1)

Publication Number Publication Date
CA2581746A1 true CA2581746A1 (en) 2006-06-08

Family

ID=36565416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002581746A Abandoned CA2581746A1 (en) 2004-10-25 2005-10-25 Staphylococcus aureus isd protein-based anti-infectives

Country Status (6)

Country Link
EP (1) EP1812066A4 (https=)
JP (1) JP2008517900A (https=)
KR (1) KR20070085457A (https=)
AU (1) AU2005310981A1 (https=)
CA (1) CA2581746A1 (https=)
WO (1) WO2006059247A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586125T3 (es) 2005-02-14 2016-10-11 Epitopix, Llc Polipéptidos de Staphylococcus aureus y métodos de uso
US20090317421A1 (en) * 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
CA2667788A1 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
NZ614557A (en) 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP6002128B2 (ja) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago プロテインA(SpA)変種に関連する組成物および方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
SG11201507141SA (en) * 2013-03-15 2015-10-29 Techulon Inc Antisense molecules for treatment of staphylococcus aureus infection
US9834768B2 (en) 2014-12-31 2017-12-05 Korea Advanced Institute Of Science And Technology Effective method for specific gene silencing using artificial small RNA
MX2021013833A (es) 2019-05-14 2022-03-17 Univ Chicago Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
CN120943954B (zh) * 2025-10-20 2026-02-06 重庆原伦生物科技有限公司 抗金黄色葡萄球菌IsdB抗体的制备及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
JP4424984B2 (ja) * 2001-06-15 2010-03-03 インヒビテックス インコーポレーテッド コアグラーゼ陰性ブドウ球菌および黄色ブドウ球菌由来の表面蛋白質を認識する、交差反応性モノクローナルおよびポリクローナル抗体
EP1412379B1 (en) * 2001-08-02 2012-01-25 The University Of Sheffield Vaccine
ATE457737T1 (de) * 2003-07-24 2010-03-15 Merck & Co Inc Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
KR20070058631A (ko) * 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물

Also Published As

Publication number Publication date
WO2006059247A2 (en) 2006-06-08
KR20070085457A (ko) 2007-08-27
EP1812066A2 (en) 2007-08-01
WO2006059247A8 (en) 2007-04-26
AU2005310981A1 (en) 2006-06-08
EP1812066A4 (en) 2010-06-30
JP2008517900A (ja) 2008-05-29
WO2006059247A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2008152447A2 (en) Staphylococcus aureus specific anti-infectives
CA2581746A1 (en) Staphylococcus aureus isd protein-based anti-infectives
CA2412504C (en) Antigenic polypeptides
US8067015B2 (en) Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
JP2001505415A (ja) Streptococcus pneumoniaeの抗原およびワクチン
Korem et al. Characterization of RAP, a quorum sensing activator of Staphylococcus aureus
US20080050361A1 (en) Staphylococcus aureas specific anti-infectives
SG182975A1 (en) Pseudomonas aeruginosa outer membrane protein pa4710
DK1784220T3 (en) BACTERIAL OBJECTIVES TO ACHIEVE IRON
Hughes et al. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59
McNitt et al. Streptococcal collagen-like protein 1 binds wound fibronectin: Implications in pathogen targeting
US8729013B2 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
JPH10113189A (ja) 新規 RNaseP
WO2006043182A2 (en) Screening assays for inhibitors of a staphylococcus aureus siderophore
US20100129349A1 (en) Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
US20070292873A1 (en) Bacterial iron acquisition targets
JPH11235183A (ja) シグナル認識粒子ポリペプチドおよびポリヌクレオチド
EP4647443A1 (en) Therapeutic variable domain of heavy chain (vhh) antibody fusions co-neutralizing alpha- and gamma-hemolysins from staphylococcus aureus
US7588773B2 (en) Methods and compositions for diagnosing and preventing a group B streptococcal infection
JP2001514025A (ja) 新規rnasep
JP2002525048A (ja) Rnasepポリペプチド
WO2008127102A1 (en) S. pnuemoniae transcytosis protein
AU2013205400A1 (en) Antigenic Polypeptides

Legal Events

Date Code Title Description
FZDE Discontinued